ArticleOrganic letters2018
Rapid Cu-Catalyzed [
Article in Organic letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.European journal of nuclear medicine and molecular imaging · 2026Review
- Synthesis and Characterization of Radio-Halogenated Talazoparib Analogues for Imaging and Radioligand Therapy.ACS chemical biology · 2026Article
- High-Yield Room-Temperature ArylACS organic & inorganic Au · 2026Article
- Scaling the production of bromine-76 and bromine-77 labeled poly-ADP-ribose-polymerase-targeted theranostics for preclinical use.EJNMMI radiopharmacy and chemistry · 2026Article
- Inhibiting NHEJ: In-Silico Approach to Stratifying DNA-PK Inhibitors, Predicting Radio-Halogenation Potential of DNA-PK Inhibitors, and Assessing AlphaFold2 Prediction Accuracy.Bioengineering (Basel, Switzerland) · 2026Article
- Astatine-211-Towards In Vivo Stable Astatine-211 Labeled Radiopharmaceuticals and Their (Pre)Clinical Applications.Medicinal research reviews · 2026Review
- Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α-Particle Therapy With Astatine 211-ParaThanatrace.International journal of radiation oncology, biology, physics · 2025Article
- Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Production ofEJNMMI radiopharmacy and chemistry · 2025Article
- Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging.EJNMMI radiopharmacy and chemistry · 2025Review
- PET and SPECT Tracer Development via Copper-Mediated Radiohalogenation of Divergent and Stable Aryl-Boronic Esters.Pharmaceutics · 2025Article
- Ethyl Pinacol Boronates as Advantageous Precursors for Copper-Mediated Radiofluorination.Organic letters · 2025Article
- PARP1-targeted alpha therapy enhances target expression.EJNMMI research · 2025Article
- Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer.EJNMMI research · 2025Article
- Copper-mediated radiochemistry: historical impact, current trends, and future possibilities.Npj imaging · 2025Review
- Simple and Efficient Synthesis ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.EJNMMI radiopharmacy and chemistry · 2024Review
- Preclinical Evaluation ofACS pharmacology & translational science · 2024Article
- The Different Strategies for the Radiolabeling of [Pharmaceutics · 2024Review
- Ligand-Enabled Copper-Mediated Radioiodination of Arenes.Organic letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Access to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.